Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 03 Jan 2017 Planned number of patients changed from 30 to 15.
- 03 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2019.
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.